Beta-Blockers in HFpEF
Beta-blockers should NOT be routinely prescribed for HFpEF as disease-modifying therapy, but should be used selectively when specific comorbid indications exist: prior myocardial infarction (within 3 years), symptomatic coronary artery disease/angina, or atrial fibrillation requiring rate control 1, 2.
When to Use Beta-Blockers in HFpEF
Specific Indications (Not for HFpEF itself):
- Post-MI patients: Use for up to 3 years following myocardial infarction 1
- Symptomatic CAD/angina: For symptom management 2
- Atrial fibrillation: For rate control, particularly with rapid ventricular response 2
- Hypertension management: May be considered as antihypertensive agent, though not first-line 2
Critical Caveat - Monitor Exercise Tolerance
Exercise tolerance must be monitored closely due to the risk of chronotropic incompetence 1. This is particularly important because HFpEF patients often have impaired chronotropic response, and beta-blockers can worsen exercise capacity by limiting heart rate response during exertion 2.
Evidence Summary
The guideline evidence is clear and consistent: beta-blockers have NOT demonstrated benefit as HFpEF-specific therapy. The 2023 ACC Expert Consensus 1 explicitly states that historical trials of beta-blockers in HFpEF were negative, and the 2022 AHA/ACC/HFSA guidelines 2 note that beta-blocker effects "need to be balanced with the potential contribution of chronotropic incompetence to exercise intolerance."
Research Evidence Context:
While observational studies suggest potential mortality benefits 3, 4, these findings are hypothesis-generating only and likely reflect confounding by indication (patients receiving beta-blockers had comorbidities like CAD or AF that independently benefit from beta-blocker therapy). The most recent meta-analysis 4 acknowledges these are observational data requiring confirmation in randomized trials.
Notably, in the DELIVER trial 5, 83% of HFpEF patients were on beta-blockers (primarily for comorbidities), and beta-blocker use did not interfere with dapagliflozin's benefits—but this doesn't establish beta-blockers as beneficial for HFpEF itself.
Dosing When Indicated
When beta-blockers are prescribed for comorbid conditions in HFpEF patients, use standard dosing for the specific indication:
- Carvedilol: Start 3.125-6.25 mg twice daily; target 25-50 mg twice daily
- Metoprolol succinate: Start 12.5-25 mg daily; target 200 mg daily
- Bisoprolol: Start 1.25 mg daily; target 10 mg daily
- Atenolol: Start 25-50 mg daily; target 100 mg daily
Important: These are HFrEF target doses 3, 6. In HFpEF, titrate based on the comorbid indication (e.g., heart rate control in AF, blood pressure in hypertension) rather than pursuing maximum tolerated doses.
Monitoring Guidelines
- Heart rate: Target depends on indication (e.g., 60-80 bpm for AF rate control)
- Exercise tolerance: Assess at each visit; consider dose reduction or discontinuation if worsening functional capacity
- Blood pressure: Avoid excessive hypotension
- Signs of chronotropic incompetence: Inability to increase heart rate appropriately with exertion, worsening dyspnea on exertion
Phenotype Considerations
Emerging evidence suggests beta-blocker effects may vary by LVEF within the HFpEF spectrum 7. Patients with LVEF 40-49% showed mortality benefit (HR 0.59), while those with LVEF ≥50% showed no clear benefit 7. However, current guidelines do not stratify beta-blocker recommendations by LVEF subgroups within HFpEF 1, 2.
Priority Therapies for HFpEF
Instead of beta-blockers, focus on evidence-based HFpEF therapies:
- SGLT2 inhibitors (dapagliflozin, empagliflozin) - Class 1 recommendation 1
- Diuretics for congestion management 1
- MRAs, ARNIs, ARBs - Class 2b recommendations for selected patients 2
- Aggressive comorbidity management: hypertension, diabetes, obesity, sleep apnea 1
Beta-blockers remain widely prescribed in HFpEF (80-90% of patients in recent trials) 8, but this reflects treatment of comorbidities rather than evidence-based HFpEF management.